LYNNTECH INC. — Department of Defense SBIR Phase II: A18-145
LYNNTECH INC. — SBIR Phase II award from Department of Defense.
- Amount
- $1,099,983
- Agency
- Department of Defense · Defense Health Program
- Program / Phase
- SBIR · Phase II
- Topic
- A18-145
- Solicitation
- 18.3
- NAICS
- —
- Place of performance
- TX
- Period
- 2020-07-06 → 2022-11-05
Description
Vascularized composite allotransplantation (VCA) is a surgical approach to treat non-salvageable injuries. Tacrolimus is the most commonly prescribed immunosuppressant to minimize tissue rejections in VCA. The safety and efficacy of tacrolimus, which has